Arca
Skip to content
Tools
Tools

THRB: Thyroid hormone receptor beta

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Nuclear hormone receptor that can act as a repressor or activator of transcription.

  • Drugs that act on it: 3
  • Approved: 1
  • In phases 1 to 3: 2
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on THRB, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Resmetirom

Phase 31

  • Eprotirome

Phase 21

  • MB07811

Phase 10

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Thyroid hormone receptor beta-1 agonist.
    ResmetiromApprovedMadrigal PharmaceuticalsSmall moleculeAgonist—12—
    EprotiromePhase 3Karo Bio ABSmall moleculeAgonist—0—
    MB07811Phase 2Viking Therapeutics, Inc.Small moleculeAgonist—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom TherapyResmetirom—Not yet recruitingRadnet Management, Inc.2026-10-06
    Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisResmetiromPhase 4RecruitingMadrigal Pharmaceuticals, Inc.2026-09-29
    Resmetirom in Patients With MASH and HFpEFResmetiromPhase 1RecruitingMadrigal Pharmaceuticals, Inc.2026-09-21
    Study of Resmetirom in Children and Adolescents With MASHResmetiromPhase 2RecruitingMadrigal Pharmaceuticals, Inc.2026-08-13
    Nutrition Intervention Combined With Resmetirom for MASHResmetiromPhase 4Not yet recruitingCity University of New York2026-07-02
    Rezdiffra Pregnancy and Lactation RegistryResmetirom—RecruitingMadrigal Pharmaceuticals, Inc.2026-04-21
    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHResmetiromPhase 2RecruitingMadrigal Pharmaceuticals, Inc.2026-01-13
    Resmiterom Efficacy & Safety in Patients With MASHResmetiromPhase 4RecruitingNabiqasim Industries (Pvt) Ltd2025-11-25

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Selective pituitary resistance to thyroid hormone
    0.78
    Generalized resistance to thyroid hormone
    0.77
    Thyroid hormone resistance, generalized, autosomal dominant
    0.71
    Glycogen storage disease due to glycogen branching enzyme deficiency
    0.69
    Thyroid hormone resistance, generalized, autosomal recessive
    0.66
    Hypothyroidism
    0.61
    Non-alcoholic fatty liver
    0.53
    Differentiated thyroid carcinoma
    0.53
    Hyperthyroidism
    0.53
    Thyroid hormone resistance syndrome
    0.51
    Obesity disorder
    0.48

    Genes and Related Targets

    Complexes and families that share a gene with this target
    Genes
    THRB

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1947, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P10828, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.